CPC A61K 47/6855 (2017.08) [A61K 47/50 (2017.08); A61K 47/545 (2017.08); A61K 47/6867 (2017.08); C07K 4/00 (2013.01); C07K 5/0205 (2013.01); C07K 5/06052 (2013.01); C07K 7/02 (2013.01)] | 8 Claims |
1. A compound of Formula (I):
or a pharmaceutically acceptable salt or solvate thereof, wherein:
Het is a mono-, bi-, or polycyclic heteroaryl ring system having 1-4 heteroatoms,
wherein a carbon atom on said ring system bound to —S(O2)— is adjacent to at least one heteroatom on said ring system, and wherein each heteroatom is independently selected from the group consisting of N, O, and S;
m is 0, 1, 2, 3, 4, or 5;
n is 0, 1, 2, 3, 4, or 5;
p is 0, 1, or 2;
q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
r is 0, 1, or 2;
s is 0, 1, or 2;
t is 0 or 1;
w is 1 or 2;
each E is independently selected from the group consisting of: —C(R1)2—, —O—C(R1)2—C(R1)2— where r is 2, and —C(R1)2—C(R1)2—O— where s is 1 or 2;
each R1 is independently selected from the group consisting of: H, C1-C6 straight or branched alkyl, C2-C6 straight or branched alkenyl, and C2-C6 straight or branched alkynyl;
R2 is C1-C10 alkyl optionally substituted with a halogen or haloalkyl, or C5-C12 aryl optionally substituted with a halogen or haloalkyl;
each X is an independently selected amino acid;
each Y is an independently selected amino acid;
each Z is an independently selected spacer element; and
D is dolastatin, MMAD, MMAE, MMAF, PF-06380101, an active agent, a moiety capable of binding to an active agent;
wherein
(a) D is selected from the group consisting of dolastatin, MMAD, MMAE, MMAF and PF-06380101; or
(b) Z is
|